Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health Plan RI analgesics Coverage & …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Formulary — Analgesics and Tiers

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered prescription analgesic drugs, their formulary tiers, and requirements (e.g., prior authorization, step therapy, quantity limits) for Neighborhood Health Plan of Rhode Island members and participating pharmacies.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyFormulary — Analgesics and Tiers
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is indicated and provide clinical documentation to support PA and any requested quantity beyond listed limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0-6Formulary tiers defined
    ManyPrior Authorization noted
    MultipleQuantity Limits present
    ~140Analgesic entries
    365dContraceptive OTC coverage

    Coverage Criteria and Formulary Controls

    Formulary coverage with utilization controls

    Covered when consistent with plan formulary and member benefits; many agents require additional utilization management controls.

    General formulary coverage: Drugs listed are on the formulary with assigned tiers; coverage is subject to member benefit and participating pharmacy requirements.

    See specific drug rows for PA, ST, QL.

    Utilization controls: For individual drugs, coverage is conditional on meeting listed requirements such as Prior Authorization (PA), Step Therapy (ST), and adherence to Quantity Limits (QL).

    High‑strength opioid formulations and specialty agents often require PA as noted in product entries.

    General coverage controls

    Products are covered when pharmacy benefit rules (tier placement) and any listed controls are met

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyFormulary — Analgesics and Tiers
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when 'PA' is indicated and provide clinical documentation to support PA and any requested quantity beyond listed limits.
    SourceLink
    On This Page
    Coverage Criteria and Formulary ControlsFormulary Drug Entries and Coding TablesKey Terms and Tier DefinitionsWhat Providers Must Do / Authorization & DocumentationInitial Therapy and Short-duration ControlsStep Therapy RulesQuantity Limits (QL) by ProductBackground and Scope
    Product-specific controls: Coverage requires adherence to listed controls: if 'PA' is indicated, prior authorization must be obtained; if 'ST' is indicated, step therapy must be satisfied; QL must not be exceeded; some products have 'High Strength Requires PA'.

    Apply product-specific QL and initial 7‑day limits where specified

    Formulary management rules

    Coverage is tier-based with utilization management applied as specified for individual products.

    Managed products: Products listed with PA require prior authorization before coverage; products with ST require step therapy be met before coverage; products with QL are covered up to the specified limit.

    Examples: EMSAM (PA), TRINTELLIX (ST; PA), INBRIJA (PA; QL 300 caps/30 days), APOKYN (ST, PA, QL 20 cartridges/30 days).

    This Formulary lists prescription drugs and the utilization controls that apply, but does not guarantee coverage. Coverage is subject to each member's benefit plan, applicable formulary tier placement, and any listed utilization management requirements. Members should consult their Certificate of Coverage or other plan materials to confirm whether a specific product is covered and any applicable conditions for coverage. Participating pharmacy requirements and plan limits may also apply.

    Low‑dose aspirin (adult low dose) is listed as an OTC formulary option with a quantity limit of 100 tablets every 30 days. It is annotated as having a $0 copay for members at risk for preeclampsia; for other indications it is noted as not covered under this OTC entry. Providers should follow the product row and member benefit rules when processing claims for low‑dose aspirin.

    The formulary includes product‑level brand/generic distinctions for some entries. For example, the generic Sarafem is specifically noted as not covered in the fluoxetine listings. Providers must verify the exact product (brand vs. generic) in the formulary row and apply the stated coverage or exclusion accordingly.

    Within the provided excerpt there are no explicit statements labelling products as 'not medically necessary'. Coverage language emphasizes plan benefit limits, formulary placement, and specific utilization controls rather than invoking a separate 'not medically necessary' determination in this segment.

    Formulary Drug Entries and Coding Tables

    No billing/CPT/HCPCS/ICD codes in this excerptmixed
    No codes listed
    Formulary drug entries (formulary product strings)mixed
    XTAMPZA ER CAP 9MGXTAMPZA ER CAP 9MG — ST, QL (60 caps every 30 days)
    XTAMPZA ER CAP 13.5MGXTAMPZA ER CAP 13.5MG — ST, QL (60 caps every 30 days)
    XTAMPZA ER CAP 18MGXTAMPZA ER CAP 18MG — ST, QL (60 caps every 30 days)
    XTAMPZA ER CAP 27MGXTAMPZA ER CAP 27MG — ST, QL (60 caps every 30 days)
    XTAMPZA ER CAP 36MGXTAMPZA ER CAP 36MG — ST, PA, QL (90 caps every 30 days); High Strength
    BELBUCA MIS 750MCGBELBUCA MIS 75MCG — ST, QL (60 films every 30 days)
    BELBUCA MIS 150MCGBELBUCA MIS 150MCG — ST, QL (60 films every 30 days)
    BELBUCA MIS 300MCGBELBUCA MIS 300MCG — ST, QL (60 films every 30 days)
    BELBUCA MIS 450MCGBELBUCA MIS 450MCG — ST, QL (60 films every 30 days)
    BELBUCA MIS 600MCGBELBUCA MIS 600MCG — ST, PA, QL (60 films every 30 days); High Strength
    1–10 of 25
    1/3
    Selected drug entries with PA/QL or special notesmixed
    DESCOVY TAB 200/25MG$0 copay when medically necessary for pre-exposure prophylaxis; copay applies for treatment
    CABENUVA SUS 400-600PA QL (1 kit every 30 days)
    CABENUVA SUS 600-900PA, QL (1 kit every 60 days); Loading dose of kit in 30 days allowed for initial fill
    TROGARZO INJ 10MG/MLTier 5 (listed), specialty injectable
    valganciclovir hcl for soln 50 mg/mlPA, QL (1000 mL every 30 days)
    EPCLUSA TAB 200-50MGPA, QL (28 tabs every 28 days)
    HARVONI TAB 45-200MGPA, QL (28 tabs every 28 days)
    PEGASYS INJPA
    Formulary drug entries with tiers and limitsmixed
    levofloxacin iv soln 25 mg/mlDrug Tier = Tier 2; QL (40 mL every day); Initial limit allows up to a 14 day course every 365 days
    entecavir tab 0.5 mgDrug Tier = Tier 5; PA, QL (30 tabs every 30 days)
    BARACLUDE SOLDrug Tier = Tier 5; PA, QL (630 mL every 30 days)
    EPCLUSA PAK 150-37.5Drug Tier = Tier 5; PA, QL (28 pellets every 28 days)
    SOVALDI PAK 200MGDrug Tier = Tier 6; ST, PA, QL (56 pellets every 28 days)
    meropenem iv for soln 1 gmDrug Tier = Tier 2; QL (6 vials every day); Initial limit allows up to a 14 day course every 365 days
    ertapenem sodium for inj 1 gmDrug Tier = Tier 2; QL (2 vials every day); Initial limit allows up to a 14 day course every 365 days
    vancomycin hcl for iv soln 1 gmDrug Tier = Tier 2; QL (2 vials every day); Initial limit allows up to a 14 day course every 365 days
    nitrofurantoin macrocrystalline cap 25 mgDrug Tier = Tier 2; Requirements/Limits = PA; High Risk Medications require PA for members age 70 and older
    azacitidine for inj 100 mgDrug Tier = Tier 5; Requirements/Limits = PA
    1–10 of 11
    1/2
    Sample listed drugs and limits (partial)NDC|drug_nameCovered
    nilotinib hcl cap 200 mglisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (120 caps every 30 days)
    pazopanib hcl tab 200 mglisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (120 tabs every 30 days)
    RYDAPT CAP 25MGlisted; Drug Tier = Tier 6; Requirements/Limits = PA, QL (224 caps every 28 days)
    SCEMBLIX TAB 20MGlisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (60 tabs every 30 days)
    sunitinib malate cap 25 mglisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (30 caps every 30 days)
    TAGRISSO TAB 40MGlisted; Drug Tier = Tier 6; Requirements/Limits = PA, QL (30 tabs every 30 days)
    VERZENIO TAB 50MGlisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (56 tabs every 28 days)
    VITRAKVI CAP 25MGlisted; Drug Tier = Tier 6; Requirements/Limits = PA, QL (180 caps every 30 days)
    XALKORI CAP 200MGlisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (120 caps every 30 days)
    LYNPARZA TAB 100MGlisted; Drug Tier = Tier 5; Requirements/Limits = PA, QL (120 tabs every 30 days)
    Formulary items with specific product stringsNDC|proprietary
    REPATHA INJ 140MG/MLREPATHA INJ 140MG/ML (listed with Tier 3; QL 3 syringes every 28 days)
    REPATHA PUSH INJ 420/3.5REPATHA PUSH INJ 420/3.5 (Tier 3; QL 1 injection every 28 days)
    REPATHA SURE INJ 140MG/MLREPATHA SURE INJ 140MG/ML (Tier 3; QL 3 pens every 28 days)
    CORLANOR SOL 5MG/5MLCORLANOR SOL 5MG/5ML (listed under Heart Failure, Tier 3)
    ENTRESTO CAP/TAB (various strengths)ENTRESTO listed (Caps/Tabs 6-6 mg through 97-103 mg) Tier 4
    Sample listed generic/combination drug formulationsmixedCovered
    atenolol & chlorthalidone 50-25 mgcombination product, Tier 2
    bisoprolol & hydrochlorothiazide 5-6.25 mgcombination product, Tier 2
    metoprolol succinate ER 25 mg (tartrate equiv)Tier 2
    sacubitril-valsartan 24-26 mglisted under sacubitril-valsartan (multiple strengths), Tier 2
    Selected specialty and managed productsmixedCovered
    APOKYN INJ 10MG/MLAPOKYN INJ 10MG/ML (listed with ST, PA, QL 20 cartridges every 30 days)
    INBRIJA CAP 42MGINBRIJA CAP 42MG (Tier 5; PA, QL 300 caps every 30 days)
    ONGENTYS CAP 25MGONGENTYS CAP 25MG (Tier 4; PA)
    EMSAM DIS 6MG/24HREMSAM transdermal (Tier 4; PA)
    TRINTELLIX TAB 5MGTRINTELLIX TAB (Tier 4; ST; PA noted)
    Common generic antidepressantsmixedCovered
    fluoxetine hcl tab 20 mgfluoxetine hcl tab 20 mg (Tier 2)
    sertraline hcl tab 50 mgsertraline hcl tab 50 mg (Tier 2)
    venlafaxine hcl tab 75 mgvenlafaxine hcl tab 75 mg (Tier 2)
    Drugs and formulary-specific QLs/Tiers shown in this segmentmixed
    fosphenytoin sodium inj 100 mg/2mlphenytoin equiv
    fosphenytoin sodium inj 500 mg/10mlphenytoin equiv
    FYCOMPA SUS 0.5MG/ML
    gabapentin cap 100 mgQL (6 caps every day)
    gabapentin cap 300 mgQL (6 caps every day)
    gabapentin oral soln 250 mg/5ml
    gabapentin tab 600 mgQL (6 tabs every day)
    gabapentin tab 800 mgQL (4 tabs every day)
    lacosamide tab 50 mg
    lacosamide tab 150 mg
    1–10 of 29
    1/3
    Formulary drug list excerptsNDC | proprietary names
    HUMULIN R INJ U-100Humulin R insulin formulation listed with Requirements/Limits = OTC; Drug Tier = Tier 4 (U-100) and Tier 3 (U-500)
    NOVOLIN INJ 70/30Novolin 70/30 listed Tier 3; Requirements/Limits = OTC; RELION not covered
    NOVOLOG INJ 100/ML and FLEXPEN and PENFILL and MIX 70/30Novolog formulations listed Tier 3
    TRESIBA (various)Tresiba injections listed Tier 3
    pioglitazone hcl tabs (15,30,45 mg)Tier 1 (15,30 mg); 45 mg listed
    SYNJARDY (various strengths)Tier 3; Requirements/Limits = ST; PA**
    GLYXAMBI (10-5 mg; 25-5 mg)Tier 3; Requirements/Limits = ST; PA**
    JARDIANCE (10 mg; 25 mg)Tier 3; Requirements/Limits = ST; PA**
    SAXENDA INJ 18MG/3MLAntiobesity agent Tier 3; Requirements/Limits = PA, QL (5 pens every 30 days)
    WEGOVY INJ (various strengths)Antiobesity agent Tier 3; Requirements/Limits = PA, QL (4 pens every 28 days)
    1–10 of 16
    1/2

    Key Terms and Tier Definitions

    Tier
    Tier rangeTier 0 through Tier 6 (Tier 0 = ACA preventive; Tier 1 = generic adherence/OTC; Tier 2 = generic; Tier 3 = preferred brand; Tier 4 = non-preferred brand; Tier 5 = preferred specialty; Tier 6 = non-preferred specialty)
    PurposeIndicates formulary grouping and relative preferred status / cost-sharing level
    Contact for questionsNeighborhood Member Services 1-833-486-5274 (TTY 711)
    PA / ST / QL
    PAPrior Authorization
    STStep Therapy
    QLQuantity Limit (maximum quantity allowed in specified time period, e.g., per 30 days)
    PA — Prior Authorization
    DefinitionPrior Authorization — approval required prior to coverage
    When requiredApplies for many listed drugs and high‑strength formulations as indicated in product rows
    ConsequenceCoverage may be denied without required PA
    QL — Quantity Limit
    DefinitionQuantity Limit — maximum quantity permitted in the specified interval (e.g., '30 g every 30 days', '10 patches every 30 days')
    ApplicationQLs are listed per product (units, mL, tabs, vials) and may include initial-fill limits
    EnforcementProviders must adhere to QL; exceeding limits may require PA or be denied
    ST — Step Therapy
    DefinitionStep Therapy — requirement to try a specified alternative therapy(s) before coverage of the listed product
    PA interactionIf step therapy requirement is not met, Prior Authorization applies
    ScopeST flags are applied to selected products (see product rows) but detailed step algorithms are not included in this excerpt
    PA — additional note (when step not met)
    PA when ST not metPrior Authorization applies if Step Therapy requirement is not met for a product (PA may be required to cover without ST compliance)
    Reference in documentHeader/footer legends state 'PA Applies if Step is Not Met'
    Provider actionSubmit PA with clinical justification when requesting override of ST
    ST — additional explanatory note
    ST flag meaningST indicates the product is subject to Step Therapy and the member must meet the step requirement before coverage
    ST appears with PA/QLSome entries show ST alongside PA and QL (e.g., certain HCV agents and migraine biologics)
    Detail levelSpecific step sequences/required failures are not provided in this excerpt; follow formulary step policies where defined
    QL — additional explanatory note
    QL usageQuantity Limits specify exact per-period caps (e.g., mL, tablets, patches, vials) for each product
    Initial-fill limitsSome liquid and immediate‑release products are 'Subject to initial 7‑day limit' as noted in product rows
    EnforcementProviders should ensure QL adherence or document rationale when requesting PA for additional quantity
    PA (short)
    PA (short)Prior Authorization
    UseRequired as indicated on product rows
    ImpactCoverage contingent on obtaining PA where listed
    QL (short)
    QL (short)Quantity Limit — maximum permitted supply in the specified interval
    ExamplesUnits, mL, tabs, vials per 28/30 days as listed per product
    ActionAdhere to listed QL or request PA with justification
    ST (short)
    ST (short)Step Therapy — try preferred agent(s) before the listed product
    If unmetPA may be required if step not met
    DocumentationProvide evidence of prior therapy trials when requesting PA related to ST

    What Providers Must Do / Authorization & Documentation

    Prior Authorization

    Prior authorization required for listed analgesics

    Obtain prior authorization when prescribing analgesic products listed with 'PA' or when Step Therapy is not met; high‑strength opioid formulations explicitly require PA before coverage.

    • PA applies if Step Therapy is not met (see header/footer legend).
    • High‑strength opioid formulations (e.g., fentanyl patches, morphine ER, hydrocodone ER) are labeled 'High Strength Requires PA'.
    Prior Authorization

    PA required for multiple analgesics including high‑strength opioids

    Prior authorization is required for many analgesic listings; prescribers must request PA for products showing 'PA' and for high‑strength opioid formulations.

    • Examples include XTAMPZA ER CAP 36MG (ST, PA, QL) and BELBUCA high‑strength films labeled 'High Strength Requires Prior Auth'.
    • Morphine, hydrocodone, fentanyl high‑strength entries indicate PA.
    Prior Authorization

    PA required for listed specialty agents (e.g., CABENUVA, valganciclovir, EPCLUSA)

    Prior authorization is required for the specialty agents shown on the formulary; entries often pair PA with quantity limits or loading‑dose rules.

    • CABENUVA kits: 'PA QL (1 kit every 30 days)' and loading dose allowance for initial fill.
    • Valganciclovir oral solution: 'PA, QL (1000 mL every 30 days)'.
    • EPCLUSA entries: 'PA, QL (28 tabs every 28 days)'.
    Prior Authorization

    PA required for listed hepatitis C agents

    Prior authorization applies to specified hepatitis C agents and their pack sizes; these entries commonly include quantity limits and, in some cases, Step Therapy.

    • EPCLUSA and HARVONI entries show 'PA, QL (28 tabs every 28 days)'.
    • SOVALDI entries include 'ST, PA, QL (28–56 pellets per 28 days)'.
    Prior Authorization

    PA required for specified hepatitis B agents (entecavir, BARACLUDE SOL)

    Prior authorization is required for select hepatitis B agents; entecavir tablets and BARACLUDE solution are labeled with PA and specified quantity limits.

    • entecavir tab 0.5 mg and 1 mg — 'Requirements/Limits = PA, QL (30 tabs every 30 days)'.
    • BARACLUDE SOL — 'Requirements/Limits = PA, QL (630 mL every 30 days)'.
    Prior Authorization

    PA required for many antineoplastics

    Many antineoplastic agents require prior authorization; oncology listings frequently include PA paired with numeric quantity limits that must be observed.

    • VENCLEXTA (venetoclax): 'PA, QL (120 tabs every 30 days)'.
    • PADCEV: 'PA, QL (21 vials every 28 days)'.
    • Multiple cytotoxic and targeted agents are annotated 'PA' in the oncology section.
    Prior Authorization

    PA plus Quantity Limits for specialty oncology agents

    Prior authorization and quantity limits apply to many specialty oral and injectable oncology agents; providers must secure PA and adhere to the QL when prescribing these drugs.

    • Nilotinib: 'PA, QL (120 caps every 30 days)'.
    • RYDAPT: 'PA, QL (224 caps every 28 days)'.
    • VERZENIO: 'PA, QL (56 tabs every 28 days)'.
    Prior Authorization

    PA indicated for specific products/classes (e.g., MULTAQ 400 mg)

    Obtain prior authorization for specific products and therapeutic classes annotated 'PA' (example: MULTAQ TAB 400MG) as shown in product rows and class headers.

    • MULTAQ TAB 400MG is annotated with 'PA'.
    • Class‑level and product rows display 'PA' indicating PA is required before coverage.
    Prior Authorization

    PA applies when Step Therapy not met

    If Step Therapy (ST) is not satisfied for a product marked 'ST', the prescriber must obtain prior authorization for coverage; the document notes 'PA Applies if Step is Not Met'.

    • Header/footer legend: 'PA Applies if Step is Not Met'.
    • Several product entries show both 'ST' and that PA will apply when ST is not met.
    Prior Authorization

    PA required for listed high‑tier/PA drugs (nitrates, PAH agents)

    Prior authorization is required for many high‑tier or high‑cost drugs listed (e.g., nitrates, pulmonary arterial hypertension agents); lack of PA may result in claim denial.

    • Ranolazine ER: 'PA, QL (360 caps every 30 days)'.
    • ADEMPAS: 'PA, QL (90 tabs every 30 days)'.
    • PAH agents (ambrisentan, bosentan, tadalafil) show 'PA' with QL.
    Prior Authorization

    Obtain PA where 'PA' or 'PA**' is shown (e.g., EMSAM, TRINTELLIX)

    Products listed with 'PA' or 'PA**' require prior authorization; examples in this segment include EMSAM and TRINTELLIX where PA and/or ST are noted.

    • EMSAM transdermal patches: 'Requirements/Limits = PA'.
    • TRINTELLIX tablets: 'Requirements/Limits = ST; PA**'.
    Prior Authorization

    PA required when indicated (e.g., pregabalin entries)

    Products annotated 'PA' or 'PA**' (e.g., pregabalin strengths) will require prior authorization; providers should not dispense without an approved PA when indicated.

    • Pregabalin caps (multiple strengths): 'Requirements/Limits = ST; PA**'.
    • Vigabatrin entries: 'PA, QL (180 packets/tabs every 30 days)'.
    Prior Authorization

    PA required for many specialty/select agents (e.g., EVRYSDI, Betaseron)

    Prior authorization is required for many specialty and selected agents (examples: EVRYSDI, AUSTEDO, BETASERON, fingolimod, glatiramer); PA often accompanies stated QLs.

    • EVRYSDI: 'PA, QL (2 bottles every 24 days or 30 tabs every 30 days)'.
    • BETASERON, fingolimod, glatiramer entries list 'PA, QL' as applicable.
    • KESIMPTA: 'PA, QL (1 pen every 28 days)'.
    Prior Authorization

    PA required for SGLT2/combo antidiabetics when ST not met (e.g., SYNJARDY)

    Prior authorization applies to several antidiabetic combination products; SYNJARDY, GLYXAMBI, and JARDIANCE are listed as ST with PA noted (PA required if step not met).

    • SYNJARDY: 'Requirements/Limits = ST; PA**'.
    • GLYXAMBI and JARDIANCE: 'Requirements/Limits = ST; PA**'.
    Step Therapy

    Step Therapy required for listed analgesics (PA if step unmet)

    Step Therapy is required for certain analgesics; if the required step(s) are not met the prescriber must obtain prior authorization for the requested product.

    • Header/footer legend: 'PA Applies if Step is Not Met'.
    • Many analgesic rows are annotated 'ST' indicating step edits apply before coverage.
    Step Therapy

    ST applies to XTAMPZA ER, BELBUCA, buprenorphine patches

    Certain specific products are subject to Step Therapy prior to coverage; examples include XTAMPZA ER, BELBUCA, and buprenorphine transdermal patches which show 'ST' in their entries.

    • XTAMPZA ER (various strengths): 'Requirements/Limits = ST, QL (60–90 caps)'.
    • BELBUCA films: 'Requirements/Limits = ST' for multiple strengths.
    • Buprenorphine TD patches: entries show 'ST, QL (4 patches every 30 days)'.
    Step Therapy

    Step Therapy noted in header/footer — PA applies if step unmet

    The document header and footers repeatedly indicate 'ST Therapy Step' and 'PA Applies if Step is Not Met', signaling that Step Therapy may be enforced for products marked ST though specific algorithms are not shown here.

    • Footer/header legend present across formulary pages referencing ST and PA interplay.
    • Specific step sequences or failure requirements are not provided in this excerpt.
    Step Therapy

    ST applies to select HCV agents (e.g., SOVALDI)

    Select hepatitis C entries list Step Therapy in addition to prior authorization and quantity limits; SOVALDI is shown with 'ST, PA, QL'.

    • SOVALDI PAK/TAB entries: 'Requirements/Limits = ST, PA, QL (28–56 pellets every 28 days)'.
    • EPCLUSA and HARVONI also show PA and QL; some packs include ST notation.
    Step Therapy

    Step Therapy referenced in footers — PA if step unmet

    Step Therapy is referenced in footers and legends across the formulary indicating ST may apply where specified on product rows; when ST is indicated PA will apply if the step is not met.

    • Footer legends: 'ST Therapy Step' present in several chunks.
    • Product rows marked 'ST' indicate step edits — details reside in full formulary.
    Step Therapy

    PA applies if required Step Therapy not completed

    The formulary notes that PA applies when Step Therapy is not met; explicit step algorithms are not included in this excerpt, so obtain PA if ST cannot be demonstrated.

    • 'PA Applies if Step is Not Met' header/footer statement.
    • Multiple product rows show ST with PA noted (e.g., pregabalin entries 'ST; PA**').
    Step Therapy

    Step Therapy headers present — follow ST where indicated

    Step Therapy headers are present on multiple pages indicating ST is a utilization control used across drug classes; prescribers must follow ST requirements where the product row indicates 'ST'.

    • 'ST Therapy Step' header appears in several chunks.
    • Products marked 'ST' require attempting preferred agents before higher‑tier drugs per the formulary.
    Step Therapy

    ST cited as utilization control (details not in this excerpt)

    Step Therapy is referenced as a utilization requirement in many product rows; specific step failures or required prior agents are not included in this excerpt.

    • Entries show 'ST' for various drugs but do not list the required prior agents in these chunks.
    • Providers should consult the full formulary for specific step algorithms.
    Step Therapy

    ST shown for ranolazine — PA applies if step not met

    Some products (e.g., ranolazine) explicitly show Step Therapy indicators with PA applying if the step is not met — obtain PA when ST cannot be documented.

    • Ranolazine ER 500 mg: 'Requirements/Limits = ST; PA**' and 'PA, QL (360 caps every 30 days)'.
    Step Therapy

    ST required for select Tier 4/specialty agents (e.g., TRINTELLIX, APOKYN)

    Step Therapy is applied to several Tier 4 medications (e.g., TRINTELLIX) and to specialty agents such as APOKYN where entries show 'ST, PA, QL'; prescribers must meet ST or obtain PA.

    • TRINTELLIX tabs: 'Requirements/Limits = ST; PA**'.
    • APOKYN injections: 'Requirements/Limits = ST, PA, QL (20 cartridges every 30 days)'.
    Step Therapy

    ST precedence noted ('ST; PA**') — pregabalin example

    When product listings display 'ST; PA**' (for example, pregabalin entries), Step Therapy must be satisfied before coverage without PA; otherwise obtain prior authorization.

    • Pregabalin multiple strengths: 'Requirements/Limits = ST; PA**'.
    • PA is required if ST is not demonstrated.
    Step Therapy

    ST applies to migraine biologics and related agents (Aimovig, Emgality, gepants)

    Step Therapy applies to specified migraine and biologic agents; AIMOVIG/EMGALITY and gepants/triptans are annotated 'ST' and often have QLs and PA flags.

    • Aimovig: 'Requirements/Limits = ST, QL (2 injections every 30 days)'.
    • Emgality: 'ST, QL (2 injections every 30 days); loading dose allowed'.
    Step Therapy

    ST required for select antidiabetic combinations (PA if step unmet)

    Step Therapy applies to certain antidiabetic combination products (SYNJARDY, GLYXAMBI, JARDIANCE) per product rows; PA applies when ST is not met.

    • SYNJARDY, GLYXAMBI, JARDIANCE entries: 'Requirements/Limits = ST; PA**'.
    • Prescribers must document ST completion or submit PA.
    Documentation Required

    Include documentation supporting PA/QL requests

    When a product row shows a Quantity Limit (QL) or initial fill limit, providers must include documentation supporting the PA/QL request (diagnosis, intended duration, and justification for exceeding QL if applicable).

    • Examples: morphine oral solutions and many tablets are 'Subject to initial 7‑day limit'.
    • QA/QL entries (e.g., EPCLUSA, CABENUVA, valganciclovir) indicate PA plus specified QLs that require justification.
    Documentation Required

    Document initial short‑duration fills (initial 7‑day limit)

    Some immediate‑release liquids and solution formulations are subject to an initial 7‑day fill limit; document the clinical rationale if requesting a larger initial supply.

    • Entries such as morphine oral solutions and other immediate‑release products are labeled 'Subject to initial 7‑day limit'.
    • Providers should document need for extended initial dosing when requesting PA.
    Documentation Required

    PA documentation expectation — include diagnosis and intended duration

    Prescribers should provide clinical documentation to support prior authorization requests for PA‑listed drugs, including diagnosis and intended duration of therapy consistent with product rows and QLs.

    • Examples where documentation is implied: CABENUVA, valganciclovir solution, EPCLUSA/HARVONI and PEGASYS injections.
    • When 'PA, QL' is shown the PA request should include clinical justification for the quantity requested.
    Documentation Required

    Provide documentation matching PA/QL requirements

    Provide documentation consistent with PA and QL entries (e.g., clinical justification for exceedance requests, previous therapy trials if ST applies) when submitting prior authorization requests.

    • IV vials and oral courses with QLs require documentation of indication and intended course length.
    • If Step Therapy applies, include evidence of prior agent trials or rationale for bypassing ST.
    Documentation Required

    Submit PA with clinical justification when 'PA' or 'PA, QL' is listed

    When a drug row shows 'Requirements/Limits = PA' or 'PA, QL (...)', submit a prior authorization request that includes clinical justification and adhere to the stated quantity limits.

    • Oncology and specialty agents frequently pair PA with QL; PA requests must support the requested quantity.
    • Failure to obtain PA or to adhere to QL may lead to denial.
    Billing Rule

    Adhere to REPATHA quantity limits in PA/claims

    Quantity limits for REPATHA products are specified and must be followed; providers should include these QLs in PA requests when applicable.

    • REPATHA INJ 140MG/ML: 'QL (3 syringes every 28 days)'.
    • REPATHA PUSH INJ 420/3.5: 'QL (1 injection every 28 days)'; REPATHA SURE INJ: 'QL (3 pens every 28 days)'.
    Documentation Required

    Follow PA/QL/ST utilization controls and document accordingly

    The formulary repeatedly lists PA, QL, and ST as utilization controls; providers must follow these controls and supply supporting documentation when requesting PA.

    • Header/footer and multiple product rows display 'PA', 'QL', and 'ST' flags.
    • Specific documentation requirements are not detailed in every entry — include diagnosis, prior treatments, and intended duration as standard PA support.
    Documentation Required

    PA often paired with QL — include dosing schedule in PA

    When PA is required, quantity limits are often specified concurrently (e.g., nitrates and some PAH agents); include the intended dosing schedule in the PA request and adhere to the QL.

    • Ranolazine and nitrates list 'PA, QL (360 caps every 30 days)'.
    • ADEMPAS entries: 'PA, QL (90 tabs every 30 days)'.
    Documentation Required

    Observe age‑specific QLs and document when requesting exceptions

    Quantity limits apply to many products and may be age‑specific; providers must observe QLs and include age‑based justification when applicable (e.g., desipramine QLs for members 65+).

    • Desipramine: 'QL applies to members age 65 and older'.
    • Nortriptyline high‑strength entries note PA/Q L applicability for older members.
    Note

    Contraceptive OTC coverage — 365‑day supply noted

    Contraceptive OTC coverage is noted (365‑day supply as of 4/1/19); providers should be aware this coverage change may affect claims processing and documentation.

    • Formulary notes: 'As of 4/1/19 contraceptives are covered for 365 days'.
    • Entries and footers repeat OTC/PA/ST legends relevant to contraceptive coverage.
    Documentation Required

    Document loading‑dose allowance for injectable migraine mAbs (Emgality)

    For injectable migraine monoclonal antibodies with ST and QL (e.g., Emgality), initial loading doses are allowed and must be documented when requesting PA for the loading regimen.

    • Emgality: 'ST, QL (2 injections every 30 days); PA = Loading dose of 2 injections in 30 days allowed for initial fill.'
    • Document initial loading dose in PA submission.
    Billing Rule

    Adhere to QLs for weight‑loss and related agents; PA for exceedance

    Quantity limits must be observed for specified products (examples: SAXENDA 5 pens/30 days; WEGOVY/ZEPBOUND 4 pens/28 days; cinacalcet QLs); request PA for quantities above these limits with supporting justification.

    • SAXENDA: 'PA, QL (5 pens every 30 days)'.
    • WEGOVY/ZEPBOUND: 'PA, QL (4 pens every 28 days)'.
    • Cinacalcet: 'PA, QL (60 or 120 tabs every 30 days)'.
    Denial Risk

    PA triggers: ST not met and high‑strength formulations

    Prior authorization is commonly triggered for analgesics when Step Therapy is not met and for high‑strength formulations; providers should secure PA or document ST completion to avoid denial.

    • Header/footer: 'PA Applies if Step is Not Met'.
    • High‑strength opioid entries are labeled 'High Strength Requires PA' and QLs—failure to obtain PA may result in denial.
    Denial Risk

    Denial risk for high‑strength opioids without PA or when QL exceeded

    High‑strength opioid formulations explicitly require prior authorization and exceeding quantity limits may trigger claim denial if PA is not obtained.

    • Fentanyl high‑strength patches: 'High Strength Requires PA'.
    • Hydrocodone ER high strengths: 'High Strength Requires PA' and specified QL/initial fill rules.
    Denial Risk

    PA required for high‑cost specialty products (e.g., CABENUVA) — denial risk if missing

    Prior authorization is required for certain high‑cost specialty products (e.g., CABENUVA) and loading‑dose rules are specified; dispensing without PA can lead to denial.

    • CABENUVA SUS entries: 'PA QL (1 kit every 30 days)' and 'Loading dose of kit in 30 days allowed for initial fill.'
    • Providers must obtain PA before dispensing CABENUVA kits.
    Denial Risk

    PA required for hepatitis C/B agents — denial risk without PA

    Prior authorization is required for listed hepatitis C and select hepatitis B agents (EPCLUSA, HARVONI, entecavir, BARACLUDE SOL); claims may be denied without PA.

    • EPCLUSA/HARVONI: 'PA, QL (28 tabs every 28 days)'.
    • entecavir and BARACLUDE SOL: 'PA, QL' entries.
    Denial Risk

    PA required for select oncology agents — denial risk if not obtained

    PA is required for selected oncology agents (e.g., azacitidine, decitabine, capecitabine, temozolomide); absence of PA or exceeding QL may result in claim denial.

    • Decitabine for inj 50 mg: 'Requirements/Limits = PA'.
    • VENCLEXTA and other antineoplastics annotated 'PA, QL'.
    Denial Risk

    Age‑based PA for nitrofurantoin (70+ years) — denial risk if undocumented

    Nitrofurantoin formulations are subject to age‑based PA for members age 70 and older; failure to document age‑based PA can cause denial.

    • Nitrofurantoin macrocrystalline 25 mg/50/100 mg and suspensions: 'Requirements/Limits = PA; High Risk Medications require PA for members age 70 and older.'
    • Document member age on PA request.
    Denial Risk

    PA required — may trigger denial if not obtained

    Drugs annotated 'Requirements/Limits = PA' will require prior authorization and may be denied without an approved PA; check product rows before dispensing.

    • Multiple product entries across classes are marked 'PA'.
    • Examples: many oncology, specialty, and some cardiovascular agents display 'PA'.
    Prior Authorization

    PA required for listed specialty products (e.g., PROLIA, TYMLOS, Lupron)

    Prior authorization is required for many specialty products (examples include deferiprone, PROLIA, TYMLOS, Lupron depot); obtain PA before dispensing to avoid denial.

    • PROLIA: 'PA, QL (60 mg every 24 weeks)'.
    • TYMLOS: 'PA, QL (1 pen every 30 days)'.
    • Lupron depot products: 'Requirements/Limits = PA'.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy and Short-duration Controls

    Initial therapy limits

    Initial short-duration controls applied to certain formulations.

    Initial 7-day limits: Multiple oral liquid and immediate‑release tablet products are subject to an initial 7‑day limit at first fill.7 days

    Applies to specified products such as morphine oral solutions and several tablet strengths; see product rows for exact QL.

    Step Therapy Rules

    Step Therapy / PA noteDetails
    Step Therapy required for certain products; Prior Authorization required if step not met.
    Document legend: 'Prior Authorization PA#* PA Applies if Step is Not Met' and 'ST Therapy Step' indicate PA will be required when ST is not satisfied.
    Product / MarkerStep Therapy implication
    XTAMPZA ER (various strengths) — listed as 'ST' in product rows
    BELBUCA (multiple film strengths) — 'ST' required prior to coverage; higher strengths also have PA/QL annotations
    Buprenorphine transdermal patches — entries show 'ST' (try preferred alternatives before coverage)
    Fentanyl patches — some strengths include 'ST' plus PA for high-strength formulations
    Header/Footer legendInterpretation
    'Prior Authorization PA#* PA Applies if Step is Not Met' (header/footer)
    'ST Therapy Step' legend (header/footer) — indicates step therapy enforcement may be applied where ST appears on product rows
    Combined implication: if ST is required and not met, PA will apply for coverage consideration
    SOVALDI entryUtilization controls
    SOVALDI PAK 200MG (and SOVALDI tabs) — listed with 'ST, PA, QL'
    ST is explicitly shown alongside PA and QL for SOVALDI packaging (e.g., 56 pellets/28 days or 28 tabs/28 days), indicating step therapy applies
    Footer legendNote
    Footer indicates 'ST Therapy Step' may apply
    Specific step therapy algorithms or required failures are not detailed in the provided footer excerpts; full formulary reference required for step specifics
    ST referencePA implication
    Step therapy is referenced in the document sections ('ST Therapy Step').
    When Step Therapy is indicated and the step is not met, Prior Authorization applies ('PA Applies if Step is Not Met').
    ST header presenceDetails / limitation
    Step therapy headers 'ST Therapy Step' are present in multiple sections indicating step edits exist
    Specific step edits or required prior therapies are referenced but not included in these excerpted chunks; consult full policy for exact step sequences
    ReferenceRequirement
    Step Therapy referenced across drug-class and product listings
    PA applies if the step requirement is not met (header/footer legend and product rows indicate this enforcement).
    DrugStep/PA note
    ranolazine ER 500 mg — product row includes 'ST; PA**' annotation
    Entry indicates step therapy is applied and prior authorization may be required if ST not met
    Agent / TierST requirement
    TRINTELLIX (vortioxetine) — Tier 4 entries list 'ST; PA**'
    Step therapy is required for certain Tier 4 agents prior to coverage; PA noted in the same entries if ST not met
    Product groupST/PA annotation
    Pregabalin formulations (multiple strengths) — listed 'ST; PA**'
    Entries indicate step therapy is required and prior authorization applies as shown by the 'ST; PA**' notation
    Policy statementImplication for coverage
    Patient must meet step therapy requirement before covering higher-tier or specified agents (documented 'ST' on product rows).
    Where ST is required, failure to meet ST will require Prior Authorization for coverage consideration (header/footer: 'PA Applies if Step is Not Met').
    Antidiabetic combinationsST / PA note
    SYNJARDY, GLYXAMBI, JARDIANCE and similar SGLT2/combination products — listed as 'ST; PA**'
    Step therapy applies to these antidiabetic combination products; Prior Authorization applies if step requirements are not met

    Quantity Limits (QL) by Product

    diclofenac sodium gel 1%
    Productdiclofenac sodium gel 1% (VOLTAREN GEL 1%)
    Quantity limit30 g every 30 days
    TierTier 2 (topical NSAID entry)
    fentanyl transdermal patch (various strengths)
    Productfentanyl transdermal patch 72hr (various strengths)
    Quantity limit10 patches every 30 days
    PA noteHigh strength patches require PA as indicated
    acetaminophen w/ codeine solution
    Productacetaminophen with codeine solution 120/12 mg per 5 mL
    Quantity limit2700 mL every 30 days; subject to an initial 7-day limit
    RequirementPrior Authorization (PA) listed
    hydrocodone ER tablets
    Producthydrocodone bitartrate ER tablets (various strengths)
    Quantity limit30 tablets every 30 days (typical QL) — some strengths have initial-fill/then increased QL)
    RequirementPA applies for listed strengths; high strength formulations require PA
    morphine sulfate oral solution example
    Productmorphine sulfate oral solution (example 10 mg/5 mL)
    Quantity limit900 mL every 30 days; subject to initial 7-day limit
    RequirementPrior Authorization (PA) listed for oral solutions
    oxycodone HCl tab 5 mg
    Productoxycodone HCl tablet 5 mg
    Quantity limit180 tablets every 30 days
    RequirementPA required; initial 7-day limit noted for some formulations
    XTAMPZA ER (various strengths)
    ProductXTAMPZA ER (various strengths) caps
    Quantity limit60–90 capsules every 30 days (90 for certain high‑strength entries)
    RequirementST applies to most strengths; high strength may require PA
    BELBUCA films
    ProductBELBUCA buccal films (various strengths)
    Quantity limit60 films every 30 days
    RequirementST applies; higher strengths list PA (High Strength Requires Prior Auth)
    nevirapine susp 50 mg/mL
    Productnevirapine oral suspension 50 mg/mL
    Quantity limitQL 1200 mL every 30 days
    TierTier 2
    nevirapine tab 200 mg
    Productnevirapine tablets 200 mg
    Quantity limitQL 60 tablets every 30 days
    TierTier 2
    CABENUVA SUS 400-600
    ProductCABENUVA SUS 400–600
    Requirement/QLPA; QL 1 kit every 30 days (loading‑dose allowance noted for initial fill)
    TierTier 6 (specialty injectable)
    valganciclovir oral solution 50 mg/mL
    Productvalganciclovir HCl oral solution 50 mg/mL
    Requirement/QLPA, QL 1000 mL every 30 days
    TierTier 5
    EPCLUSA TAB 200-50MG
    ProductEPCLUSA (sofosbuvir/velpatasvir) tablet 200/50 mg
    Requirement/QLPA, QL 28 tablets every 28 days
    TierTier 5
    ceftriaxone sodium for injection
    Productceftriaxone sodium for injection (various strengths)
    Quantity limitQL 2 vials every day; initial limit allows up to a 14‑day course every 365 days
    TierTier 2
    levofloxacin IV soln 25 mg/mL
    Productlevofloxacin IV solution 25 mg/mL
    Quantity limit40 mL (per day)
    NoteInitial limit allows up to a 14‑day course every 365 days
    vancomycin cap 125 mg
    Productvancomycin capsule 125 mg
    Quantity limit80 capsules
    IntervalEvery 10 days (as listed)
    meropenem IV for soln 1 gm
    Productmeropenem IV for solution 1 g vial
    Quantity limit6 vials every day
    Initial-course noteInitial limit allows up to a 14‑day course every 365 days
    ertapenem sodium for injection 1 gm
    Productertapenem sodium for injection 1 g
    Quantity limit2 vials every day
    Initial-course noteInitial limit allows up to a 14‑day course every 365 days
    EPCLUSA PAK 150-37.5
    ProductEPCLUSA PAK 150‑37.5
    Quantity limit28 pellets every 28 days
    RequirementPA applies
    SOVALDI PAK 200MG
    ProductSOVALDI PAK 200 mg
    Quantity limit56 pellets every 28 days
    RequirementST, PA, QL (as listed)
    VENCLEXTA tabs
    ProductVENCLEXTA (venetoclax) tablets
    Quantity limit120 tablets every 30 days; starter pack 1 every 28 days
    RequirementPA applies
    PADCEV
    ProductPADCEV (enfortumab vedotin) injection
    Quantity limit21 vials every 28 days; 15 vials every 28 days for 30 mg strength (strength‑specific QL)
    RequirementPA applies
    POMALYST / REVLIMID / THALOMID
    ProductsPOMALYST / REVLIMID / THALOMID
    Quantity limitsQLs vary by product (examples: POMALYST 21 caps/28 days; REVLIMID 28 caps/28 days; THALOMID 112 caps/28 days)
    RequirementPA applies for these agents
    Multiple kinase/targeted agents — examples
    CategoryMultiple kinase / targeted agents (examples)
    Example QLsdasatinib 30 or 90 tabs/30 days; everolimus 30 tabs/30 days; imatinib up to 120 tabs/30 days (product‑specific)
    RequirementPA and QL commonly apply to these agents
    nilotinib HCl cap 200 mg
    Productnilotinib HCl capsules 200 mg
    Quantity limit120 capsules every 30 days
    RequirementPA applies
    RYDAPT cap 25 mg
    ProductRYDAPT capsules 25 mg
    Quantity limit224 capsules every 28 days
    RequirementPA applies
    VITRAKVI cap 25 mg
    ProductVITRAKVI capsules 25 mg
    Quantity limit180 capsules every 30 days
    RequirementPA, QL apply
    VERZENIO tab 50 mg
    ProductVERZENIO tablets 50 mg
    Quantity limit56 tablets every 28 days
    RequirementPA, QL apply
    LYNPARZA tab 100 mg
    ProductLYNPARZA tablets 100 mg
    Quantity limit120 tablets every 30 days
    RequirementPA applies
    REPATHA INJ 140MG/ML
    ProductREPATHA injection 140 mg/mL (syringe)
    Quantity limit3 syringes every 28 days
    RequirementQL listed for REPATHA presentations
    REPATHA PUSH INJ 420/3.5
    ProductREPATHA PUSH INJ 420 mg/3.5 mL
    Quantity limit1 injection every 28 days
    RequirementQL listed
    REPATHA SURE INJ 140MG/ML
    ProductREPATHA SURE INJ 140 mg/mL (pen)
    Quantity limit3 pens every 28 days
    RequirementQL listed
    REPATHA INJ 14OMGIML
    ProductREPATHA 140 mg (alternate syringe code)
    Quantity limit3 syringes every 28 days (alternate listing)
    RequirementQL listed
    REPATHA PUSH INJ 420/3.5 (alt)
    ProductREPATHA PUSH INJ 420/3.5 (alternate listing)
    Quantity limit1 injection every 28 days
    RequirementQL listed
    REPATHA SURE INJ 14OMGIML (alt)
    ProductREPATHA SURE INJ 14OMGIML (alternate)
    Quantity limit3 pens every 28 days
    RequirementQL listed
    ranolazine ER 500 mg
    Productranolazine ER 500 mg
    Quantity limit360 capsules every 30 days
    RequirementPA applies; QL listed
    isosorbide dinitrate / isosorbide mononitrate formulations
    Productsisosorbide dinitrate / isosorbide mononitrate formulations
    Quantity limit360 tablets/capsules every 30 days (per listings)
    RequirementPA and QL listed for many nitrate formulations
    ADEMPAS (riociguat)
    ProductADEMPAS (riociguat)
    Quantity limit90 tablets every 30 days
    RequirementPA applies
    ambrisentan
    Productambrisentan
    Quantity limit30 tablets every 30 days
    RequirementPA applies
    bosentan
    Productbosentan
    Quantity limit60 tablets every 30 days
    RequirementPA applies
    tadalafil (PAH)
    Producttadalafil (for PAH)
    Quantity limit30 tablets every 30 days (some entries 60 tabs)
    RequirementPA applies
    TYVASO
    ProductTYVASO (inhaled treprostinil)
    Quantity limit28 ampules every 28 days
    RequirementPA, QL apply
    VENTAVIS
    ProductVENTAVIS (iloprost) solution
    Quantity limit270 ampules every 30 days
    RequirementPA, QL apply
    desipramine HCl tabs
    Productdesipramine HCl tablets (various strengths)
    Quantity limitQL 30–120 tablets every 30 days depending on strength; QL may apply to members age 65+
    NoteHigh‑strength entries may require PA for older members
    APOKYN INJ 10MG/ML
    ProductAPOKYN injection 10 mg/mL cartridges
    Quantity limit20 cartridges every 30 days
    RequirementST, PA, QL listed
    INBRIJA CAP 42MG
    ProductINBRIJA capsules 42 mg
    Quantity limit300 capsules every 30 days
    RequirementPA and QL apply
    NAYZILAM SPR
    ProductNAYZILAM nasal spray
    Quantity limit10 units
    IntervalPer 30 days as listed
    vigabatrin powder pack 500 mg
    Productvigabatrin powder pack 500 mg
    Quantity limit180 packets every 30 days
    RequirementPA applies (and QL)
    vigabatrin tab 500 mg
    Productvigabatrin tablets 500 mg
    Quantity limit180 tablets every 30 days
    RequirementPA applies
    ADZENYS XR
    ProductADZENYS XR (various strengths)
    Quantity limit60–120 tablets every 30 days depending on strength
    RequirementQL applies
    amphetamine/dextroamphetamine (various)
    CategoryAmphetamine/dextroamphetamine formulations (various)
    Quantity limits60–180 capsules/tablets every 30 days depending on formulation/strength
    RequirementQL applies
    methylphenidate chew tabs / solution
    ProductsMethylphenidate chew tabs and solution examples
    Quantity limits300 chew tabs or 3000 mL solution every 30 days (examples)
    RequirementQL applies by formulation
    lisdexamfetamine caps/chew tabs
    Productlisdexamfetamine (caps/chew tabs) — examples
    Quantity limits30–60 caps/tabs every 30 days depending on strength
    RequirementQL applies
    gabapentin (multiple strengths)
    Productgabapentin (multiple strengths)
    Quantity limitTypically QL 4–6 capsules/tablets per day (strength‑dependent)
    RequirementQL applies
    lisdexamfetamine chew tab 30 mg
    Productlisdexamfetamine dimesylate chew tab 30 mg
    Quantity limit60 tablets every 30 days
    RequirementQL applies
    lisdexamfetamine chew tab 40 mg
    Productlisdexamfetamine dimesylate chew tab 40 mg
    Quantity limit30 tablets every 30 days
    RequirementQL applies
    methylphenidate chew tab 5/10/2.5 mg
    Productmethylphenidate chew tab 2.5/5/10 mg examples
    Quantity limit300 chew tablets every 30 days
    RequirementQL applies
    methylphenidate solution 5 mg/mL
    Productmethylphenidate solution 5 mg/mL
    Quantity limit3000 mL every 30 days
    RequirementQL applies
    Emgality inj 100 mg/mL
    ProductEmgality injection 100 mg/mL
    Quantity limit3 injections every 30 days
    NoteSome presentations have 2 injections/30 days (loading dose rules may apply)
    Emgality inj 120 mg/mL
    ProductEmgality injection 120 mg/mL
    Quantity limit2 injections every 30 days
    NoteLoading dose allowance may be specified for initial fill
    Evrysdi sol
    ProductEvrysdi solution
    Quantity limit2 bottles every 24 days (example listing)
    RequirementPA and QL may apply
    modafinil tab 100/200 mg
    Productmodafinil tablets 100/200 mg
    Quantity limit60 tablets every 30 days
    RequirementQL applies
    sodium oxybate solution 500 mg/mL
    Productsodium oxybate solution 500 mg/mL
    Quantity limit540 mL every 30 days
    RequirementPA and QL apply
    buprenorphine/naloxone SL film
    Productbuprenorphine/naloxone sublingual film (various strengths)
    Quantity limit60–90 units every 30 days depending on strength
    RequirementQL applies
    SAXENDA INJ 18MG/3ML
    ProductSAXENDA injection 18 mg/3 mL
    Quantity limit5 pens every 30 days
    RequirementPA and QL apply
    WEGOVY INJ
    ProductWEGOVY injection (various strengths)
    Quantity limit4 pens every 28 days
    RequirementPA and QL apply
    ZEPBOUND INJ
    ProductZEPBOUND injection (various strengths)
    Quantity limit4 pens every 28 days
    RequirementPA and QL apply
    cinacalcet tabs
    Productcinacalcet HCl tablets (30, 60, 90 mg)
    Quantity limit60 tablets every 30 days (30/60 mg); 120 tablets every 30 days (90 mg)
    RequirementPA and QL apply
    PROLIA INJ 60MG/ML
    ProductPROLIA injection 60 mg/mL
    Quantity limit60 mg every 24 weeks
    RequirementPA and QL apply
    TYMLOS INJ
    ProductTYMLOS injection
    Quantity limit1 pen every 30 days
    RequirementPA and QL apply
    Various contraceptives and devices
    CategoryVarious contraceptives and devices (examples)
    Examples of QLIUDs/implants: QL 1 every 300 days; condoms: QL 12 every 30 days
    Coverage noteMany contraceptives listed as Tier 0 with coverage notes (as of 4/1/19)

    Background and Scope

    This formulary segment focuses on analgesic medications — including NSAIDs, topical agents, opioid products, and other pain therapies — and documents assigned tiers, prior authorization and step therapy requirements where applicable, and product‑specific quantity limits. Utilization management controls such as PA, ST, and QL are applied per product row; examples include topical diclofenac QL and high‑strength opioid PA requirements.